NEW YORK (GenomeWeb News) – Genome customization firm Cellectis bioresearch today announced it has won a five-year, $9.5 million contract from the National Institutes of Health for work directed at induced pluripotent stem cells.
Under the terms of the contract, Cellectis bioresearch will provide services to NIH and certain other government agencies. The company will generate iPS cell lines of clinical grade and differentiate iPS cells toward specific tissue cell type of clinical grade.
The contract, which has a maximum order limit of $9,509,000, is the largest secured by Cellectis bioresearch, CEO Marc Le Bozec said.
Based in Paris, with an office in Cambridge, Mass., Cellectis bioresearch is a subsidiary of the Cellectis Group.